Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...
Philip Gregory, chief scientific officer at bluebird, said the latest analysis showed that the integration site of the vector was in a gene called VAMP4. bluebird bio's Philip Gregory VAMP4 has no ...
Given the recent M&A activity associated with companies such as 2seventy Bio, and BlueBird, and considering Precision Biosciences low market cap ($40 million), I wouldn’t be surprised if the ...
It also follows the decision by gene therapy pioneer bluebird bio to sell itself to ... and bought Bamboo Therapeutics to provide a viral vector platform for gene therapy delivery and early ...
Cancer Gene Therapy Market to Soar to US$ 17.57 Billion by 2033, Registering a Robust CAGR of 18.24%
The global Cancer Gene Therapy Market was valued at US$ 3.89 billion in 2024 and is projected to experience a remarkable surge to US$ 17.57 billion by 2033, growing at a compelling CAGR of 18.24% ...
Pre-Market: 6:21:05 a.m. EDT Loading Chart for BLBD ...
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback